Head of Human Resources - France IM, OneHR France
About the job
- A minimum of a Bachelor's degree in Human Resources or a related field is required.
- At least 8 years of professional experience, including managerial experience coaching and leading talent, and at least 5 years of progressive HR or HR-related experience are required.
- Experience managing, planning, and implementing projects and business support initiatives is required.
- Relationship management, coaching, and collaboration skills are required.
- Influence, solution-shaping, negotiation, and partnership skills are required.
- Experience using data to influence senior business leaders is required.
- Strong interpersonal, consultative, and facilitation skills are required.
- Ability to understand and integrate internal and external business drivers and financial metrics to drive talent outcomes for the business is required.
- Experience with innovative change efforts, including developing and implementing detailed change management plans, is required.
- Strong Microsoft Office and related talent management technology skills are required.
- Experience driving strategic change to meet changing business needs and exploring new business models is required.
- Create and deploy the HR agenda for business teams, aligned with HR, business, and shared-services strategies, and integrate HR priorities into business plans.
- Evaluate business, financial, and other drivers across functional groups, countries, and regions to inform HR solutions, including tracking performance and diagnosing capability gaps.
- Execute significant organizational design efforts, including legal reviews, preparing managers to lead notifications, and developing and executing notification and exit plans.
- Develop trusted partnerships or coaching relationships with internal or external leaders to enhance their impact.
- Partner with business leadership to provide strategic context for communications plans.
- Support acquisition and divestiture activity, including due diligence and integration.
- Lead organizational design efforts to position the business for the future.
- Guide and support change plans to restore organizational effectiveness following notifications, and diagnose and design solutions after organizational design execution.
- Identify critical business capability needs and partner with business leaders to develop and execute strategies to strengthen the organization.
- Recommend strategies with business or HR partners that anticipate and address future changes in business conditions.
- Create and deploy talent strategies to attract, develop, reward, and retain talent, including succession pipelines and critical capability building.
- Own and drive talent management for the business, function, or geography; set priorities, establish talent-review cadence aligned to the global calendar, align talent pools, and measure progress using talent metrics such as retention, movement, and diversity representation.
- Partner with Talent Acquisition to define sourcing and hiring strategies for critical capabilities and ensure diverse candidate slates.
- Lead succession planning for critical business and function roles, assess pipeline strength, and develop plans to strengthen it.
- Execute the Inclusion strategy.
- Partner across the OneHR model to assess current capabilities and enhance them through buy, build, or borrow strategies with Talent Acquisition/Access and J&J Learn.
- Execute workforce planning, including assessments of the organization and talent, in alignment with business strategy and resourcing needs.
- Support career planning and pathing as part of the talent strategy.
- Lead talent-planning exercises deeper within the organization, focused on critical capabilities.
- Consult with Employee Relations/Labor Relations on local strategy and conduct works-council consultations.
- Identify and diagnose business talent needs through business and analytical acumen and effective analysis.
- Develop onboarding plans for new leaders.
- Coach leaders on employee performance, stakeholder interactions, and team effectiveness.
- Consult on disciplinary actions resulting from Employee Relations investigations and support associated employee and manager coaching.
- Develop trusted partnerships and coaching relationships with leaders and teams to build leadership capabilities and enhance leader impact.
- Partner with business leaders on team-effectiveness program options and facilitator selection.
- Ensure meaningful engagement, development, energy, and effective performance of the team.
- Advise business Credo Action/Engagement Teams and Business Employee Resource Groups.
- Partner with business leaders to shape culture and employee engagement strategies informed by Our Credo and employee sentiment.
- Identify, define, and help build key mindsets and behaviors for the business with business leaders.
- Drive a culture of Our Credo, growth, collaboration, and inclusion within teams.
- Experience supporting multiple business functions and working in various industries, preferably within large, complex organizations.
- Business alignment, change leadership, coaching, developing others, employee retention, HR business partnership, HR operational planning and organizing, HR strategic management, human resources consulting, human resources law, inclusive leadership, interpersonal influence, leadership, organizational change management, problem solving, and talent management are listed as preferred skills.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.